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Summary A total of 169 colorectal adenocarcinomas, obtained from patients with a median follow-up of 6.5 years, were studied with
immunohistochemical staining on cryosections using a monoclonal anti-tenascin antibody to evaluate the possible association between the
staining patterns and tumour stage, tumour differentiation and survival. We found two different staining patterns in the tumour stroma - a
diffuse stromal fibrillar staining in 92 out of 169 (54%) tumours and a subglandular staining in the remaining 77 tumours. When the entire
group of patients (P< 0.01) and the group of potentially cured patients (P< 0.03) were analysed univariately, it was found that diffuse stromal
fibrillar staining was associated with a shorter survival time than subglandular staining. In a multivariate analysis, the Dukes' stage and age
were independent prognostic factors, whereas the tenascin expression did not retain a clear independent relationship to survival (P= 0.06).
Hence, it appears that the tumour expression of tenascin may be a potential prognostic marker in colorectal cancer, in so far as a diffuse
stromal fibrillar staining pattern seems to indicate an increased risk of poor outcome. However, after adjustment for age and Dukes' stage, the
additional prognostic value of tenascin remains to be established in further analyses.
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Tenascin is a large hexameric extracellular matrix protein that is
present during embryonic development but essentially absent in
normal adult tissues (Schenk andChiquet-Ehrismann, 1994) and is
expressed only at low levels or in a very restricted distribution.
Several tenascin isoforms have been described (Siri et al, 1995).
Tenascin has been suggested to be of importance in the normal
healing process and in tumours, in which its role is presumed to be
connected with cell adhesion and detachment, cell growth, cell
migration and angiogenesis (Mackie et al, 1988; Ekblom and
Aufterheide, 1989; Erickson and Bourdon, 1989; Chiquet-
Ehrismann, 1993; Hahn et al, 1995; Joshi et al, 1995). It has been
proposed that, although tenascin has no cell adhesion activity, it
does affect the cell shape and, thus, may inhibit cell attachment to
other extracellular proteins, including fibronectin (Mackie, 1994).
It is also thought that tenascin plays a role in coordinating the
provisional extracellular matrix surrounding the cancer tissue
(Sakakura and Kusakabe, 1994).
Several reports have shown an up-regulation of tenascin in
various tumour stroma, such as breast (Moch et al, 1993; Shoji et
al, 1993; Yoshida et al, 1995), lung (Natali and Zardi, 1989),
prostatic (Ibrahim et al, 1993) and gastric carcinomas (Ikeda et al,
1995; Ilunga andIriyama, 1995). Studies ofthis putative markerof
the tumour matrix are also of considerable interest in colorectal
cancer (Sugawara et al, 1991; Riedel et al, 1992; Sakai et al, 1993;
Hauptmann et al, 1995; Riedel et al, 1995) because ofthe potential
involvement oftenascin (ortenascin-like proteins) in cell adhesion
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and invasion during the metastatic process. Moreover, diagnostic
and possibly therapeutic monoclonal antibodies, specific for the
larger tenascin isoforms present in tumours, have been developed
(Leprini et al, 1994).
In order to search for prognostic markers in colorectal cancer,
especially in Dukes' stages B and C, which are associated with a
high relapse rate (and for which adjuvant therapy could be an
option), we investigated the expression oftenascin in 169 tumours
from aprospective series ofpatients resected forcolorectal cancer.
The staining patterns were evaluated in relation to common
clinicopathological variables and patient survival time.
MATERIALS AND METHODS
Patients
Tumour samples were collected from 169 consecutive patients
operated on for colorectal cancer between January 1987 and
November 1992. There were 72 men and 97 women of ages
ranging from 40 to 92 (median 71) years. One hundred and forty-
seven tumours (87%) were resected for cure: 36 in Dukes' stage A,
79 in stage B and 32 in stage C. The remaining 22 patients had
perioperatively detected distant metastases andunderwent a pallia-
tiveresection. Tumourdifferentiation was characterized as good in
22 tumours, moderate in 110 and poor in 37. At follow-up in
October 1995, 65 (39%) patients had died from other causes,
without any indication oftumour relapse. Median survival time of
living patients was 83 months (range 39-105 months).
Tumour biopsies
Tumourbiopsies were snap frozen in dry-ice isopentane and stored
at -70°C. Routine biopsies were taken for histopathological
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Figure 1 Section from a colorectal adenocarcinoma stained with anti-
tenascin antibody using an immunoperoxidase method showing typical (A)
subglandular pattern and (B) diffuse pattern. Magnification x250
classification. The tumours were graded according to the WHO
classification (Morson and Sobin, 1976) and were staged
according to the Dukes' classification system (Dukes and Bussey,
1958). Dukes' stage A indicates that the tumour growth does not
extend beyond the muscularis propria, while this is the case in
stage B. In Dukes' stageC, there is metastatic tumourgrowth in the
regional lymph nodes, and in stage D there are distant metastases.
Immunohistochemical detection
Acetone-fixed 6-tm cryosections were stained with the mouse
monoclonal antibody BC-4 to tenascin (kindly provided by Dr P
Ekblom, Department of Zoophysiology, Biomedical Center,
University of Uppsala, Sweden). The avidin-biotin method,
containing a peroxidase conjugate, was used (ABC Elite, Vector,
Burlingame, CA, USA). The primary antibody was used at a dilu-
tion of 1:125 in phosphate-buffered saline supplemented with 5%
normal horse serum and 1% bovine serum albumin, and was incu-
batedwithtissues for60min atroomtemperature. Theprimary anti-
body was then omitted and was replaced by either dilution buffer or
normal mouse IgG, as negative controls. The secondary antibody,
biotinylated horse anti-mouse IgG from Vector Laboratories, was
used at adilution of 1:200 and was incubated for 30 min.
Immunohistopathological evaluation
Tenascin staining patterns wereexaminedby light microscopy, at a
magnification of x125. Coded slides from all 169 tumours were
evaluated without prior knowledge of tumour stage or clinical
outcome. In orderto assess the interobserver agreement, two ofthe
authors (UK, GL) evaluated 20 randomly selected and blinded
sections.
Statistical methods
The Cox proportional hazards model was used (Lawless, 1992) in
both the univariate and the multivariate survival analyses.
Likelihood ratio and Wald tests were used in the testing. Survival
curves were constructed using the Kaplan-Meier method, and
differences between curves were tested using the log-rank test.
The proportion ofpatients with diffuse tenascin expression among
different categories of Dukes' stage and differentiation was
analysed using the logistic regression model. Trend tests were also




Extensive fibrillar tenascin positivity was constantly seen in the
tumour matrix, whereas tumour epithelial cells were entirely nega-
tive. Tenascin expression was generally seen in muscularis
mucosae, in muscularis propia and in the vessel walls. Minimal
staining, if any, was detectable in the adjacent normal bowel wall.
Table 1 Tenascin expression in colorectal cancer and its relation to tumour stage and tumour differentiation
Cases n Tenascin diffuse staining n (%) Death in cancer (%) Tenascin subglandular staining n Death in cancer (%)
Dukes' stage
A 36 18 (50) 4 (22) 18 1 (6)
B 79 38 (48) 15 (39) 41 6 (15)
C 32 21 (65) 11 (52) 11 6 (55)
D 22 15 (68) 15 (100) 7 7 (100)
Tumour differentiation
Good 22 6 (27) 2 (33) 16 2 (12)
Moderate 110 62 (56) 25 (40) 48 14 (29)
Poor 37 24 (65) 18 (73) 13 4 (31)
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Figure 2 Life-table plots for (A) all 169 patients (Dukes' stages A-D) and
(B) the 147 patients operated on for cure (Dukes' stages A-C).-,
Subglandular tenascin pattern; - - -, diffuse tenascin pattern. 0, complete
responses (i.e. patients who have died from cancer); +, censored responses
(i.e. patients who are alive or who have died from causes other than cancer)
There were two different tenascin stromal fibrillar staining
patterns - a subglandular pattern, in which the tenascin staining
outlined the border ofthe malignant tubules, and a diffuse pattern,
characterized by diffuse interglandular stromal fibrillar distribu-
tion (Figure 1 A and B). Either staining pattern was invariably seen
throughout the interglandular stroma in each section. We did not
see any correlation between tenascin expression and the number of
microvessels in the tumour sections. No interobserver disagree-
ment was seen.
Tenascin stainings and tumour stage, tumour
differentiation and survival time
Dukes' stages C and D showed a tendency to have an increased
proportion of diffuse tenascin staining. Compared with the refer-
ence category, Dukes' stage A, the increase was not significant (P-
values 0.20 and 0.18), but a trend test yielded a result that was
almost statistically significant (P = 0.06). There also appeared to
be a connection between tumour differentiation and tenascin
staining pattern, with a higher proportion ofdiffuse pattern among
patients with moderately and poorly differentiated tumours (P-
values 0.02 and 0.01 respectively; Table 1). The table also shows
that the number of patients who died from cancer, or from other
causes but with cancer, varied according to the Dukes' stage,
tumour differentiation and tenascin staining pattern.
Table 2 Univariate analyses showing the effects of age, tenascin expression,
tumour differentiation and Dukes' stages on survival in patients resected for
colorectal cancer
Variable 3 s.e.(1) Pvalue RH
Age (continuous) 0.02 0.01 NS 1.02
Tenascin expression
Subglandular 0.00 (ref) 1.00
Diffuse 0.73 0.27 0.007 2.07
Tumour differentiation
Good 0.00 (ref) 1.00
Moderate 0.27 0.41 NS 1.31
Poor 1.14 0.44 0.01 3.11
Dukes' stage
A 0.00 (ref) 1.00
B 0.59 0.47 NS 1.80
C 1.51 0.47 0.001 4.53
D 3.51 0.49 0.0001 33.68
RH, relative hazard. Number of patients, 169; number of deaths, 65.
Table 3 Multivariate analysis showing the effects of age, tenascin
expression, tumour differentiation and Dukes' stages on survival in patients
resected for colorectal cancer
Variable s.e.(f) P-value RH
Age (continuous) 0.039 0.014 0.005 1.04
Tenascin expression
Subglandular 0.00 (ref.) 1.00
Diffuse 0.54 0.28 0.056 1.72
Tumour differentiation
Good 0.00 (ref) 1.00
Moderate 0.38 0.42 NS 1.47
Poor 0.49 0.47 NS 1.63
Dukes' stage
A 0.00 (ref) 1.00
B 0.63 0.47 NS 1.86
C 1.35 0.48 0.005 3.90
D 3.69 0.52 0.0001 39.90
RH, relative hazard. Number of patients, 169; number of deaths, 65.
Altogether, 39 (51%) ofthe 77 patients with tumours displaying
a subglandular staining pattern were alive after 5 years, while the
corresponding figure for the 92 patients with diffuse staining was
38 (41%). The relation between the type of tenascin expression
and the cancer-specific survival time, when analysed with a life-
table technique, showed a significantly shorter survival time for
those patients whose tumours showed a diffuse pattern than for
those who showed a subglandular pattern. This was valid for both
the entire group ofpatients (log-rank, P < 0.01, Figure 2A) and the
subset of patients with tumours in Dukes' stage A-C (log-rank,
P < 0.03, Figure 2B). Univariate survival analyses showed a
significant relationship to survival for Dukes' stage, tumour
differentiation and diffuse tenascin staining pattern (Table 2). In a
multivariate analysis encompassing all patients, Dukes' stage and
age were independent prognostic factors for survival, whereas the
diffuse tenascin staining pattern showed a borderline (P = 0.056)
significant relationship to the survival time (Table 3). The relative
British Journal ofCancer(1997) 76(4), 526-530 0 CancerResearch Campaign 1997Tenascin in colorectal cancer 529
hazard (RH) for patients with diffuse expression was 1.72 (95%
confidence limits 0.98-2.99). Tumour differentiation lost its rela-
tionship to survival.
DISCUSSION
All specimens investigated exhibited strong tenascin staining of
the interglandular tumour stroma, whereas they predominantly
lacked tenascin staining in the adjacent normal bowel wall, thus
indicating tenascin up-regulation in malignancy. This finding has
been described by others in colorectal cancer (Sugawara et al,
1991; Riedel et al, 1992, 1995; Sakai et al, 1993; Hauptmann et al,
1995) and in several other tumour types (Natali and Zardi, 1989;
Ibrahim et al, 1993; Moch et al, 1993; Shoji et al, 1993; Ikeda et al,
1995; Ilunga and Iriyama, 1995; Yoshida et al, 1995). Like
Sugawara et al (1991), we also found two different staining
patterns. In contrast, Riedl et al (1992) did not discriminate
various tenascin staining patterns but reported various degrees of
extensive positivity in the basement membranes of colorectal
carcinomas. Interestingly, Riedl et al (1995) reported that high
serum levels oftenascin reflected metastatic disease.
Consistent with the findings of Sugawara et al (1991), we were
able to demonstrate distribution differences between the two
tenascin staining patterns according to Dukes' stage and tumour
differentiation. In addition, we established a significantly shorter
survival time for patients showing the diffuse tenascin staining
pattern than for patients showing the subglandular tenascin
staining pattern. A possible explanation forthis difference in prog-
nosis between the two staining patterns could be that subglandular
tenascin may fulfil a protective function in preventing tumour
invasion and/or metastases, as suggested previously (Sakakura and
Kusakabe, 1994; Siri et al, 1995).
It is recognized that until now the Dukes' classification has been
the best known prognostic factor in colorectal cancer (Lindmark et
al, 1994; Bosman, 1995). However, there is also considerable vari-
ation in prognosis within the Dukes' stages (Newland et al, 1987;
Lindmark et al, 1994). Bentzen et al (1988) showed, for example,
that some subgroups of Dukes' stage C patients had better prog-
nosis than some subgroups of Dukes' stage B patients. For thera-
peutic and surveillance reasons, it is ofimportance to find stronger
prognostic factors otherthan the original Dukes' classification, i.e.
to be able to predict those patients with tumours in Dukes' stages
B and C who are likely to have micrometastases requiring addi-
tional immediate treatment. Strong efforts have been made in the
search for such markers that can replace or add information to that
of the Dukes' stage. Jass et al (1987) have reported a prognostic
scoring system that was found to be superior to that ofthe Dukes'
stage for rectal cancer. The system considered the character ofthe
invasive margin, peritumoral lymphocytic infiltration, local spread
and number of metastatic lymph nodes. However, this scoring
classification system has not been established, as yet, in clinical
pathological practice, probably because the pathological examina-
tion is rather time-consuming. Several tumour markers also
provide additional prognostic information, but their clinical rele-
vance is yet to be defined as they mainly identify patients who
already have metastases at diagnosis (Stahle et al, 1988; Lindmark
et al, 1995). We have recently observed that the number of
microvessels in tumour sections contributes to the prognosis
prediction in colorectal cancer (Lindmark et al, 1996). However,
in the present study, we did not see any correlation between the
tenascin expression and the number of microvessels in the tumour
sections. Tumourcell DNA ploidy and cell proliferation, measured
by flow cytometry, have not turned out to be strong prognostic
factors beyond that ofDukes' stage in colorectal cancer (Lindmark
et al, 1991; Bottger et al, 1993). This also appears to be the case
for p53 overexpression, although some studies have shown a
correlation with prognosis (Mulder et al, 1995; Kressner et al,
1996). Recent molecular studies suggest that the process of
tumorigenesis in colorectal cancer proceeds through a series of
genetic alterations (Fearon and Vogelstein, 1990). Two reports
have shown that allelic loss on chromosome 18q (DCC gene) is
associated with poor prognosis in Dukes' stage B (O'Connel et al,
1992; Jen et al, 1994). Further studies are needed, however, to
clarify how genetic alterations can contribute to prognosis. As yet,
no single studied prognostic marker has proved to be better for
prediction than the Dukes' stage.
To summarize, the stromal fibrillar distribution of tenascin
appears to be a potential prognostic marker. We were able to
discriminate, on the basis of significant tenascin staining differ-
ences, between living patients with no evidence of disease and
those who had died from cancer after a potentially curative resec-
tion forcolorectal cancer. However, the strength ofthis finding was
reduced after adjustment for the effects ofDukes' stage and age.
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